$2.49
-0.01 (-0.40%)
Open$2.52
Previous Close$2.50
Day High$2.58
Day Low$2.46
52W High$4.00
52W Low$1.65
Volume—
Avg Volume313.5K
Market Cap244.26M
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+855.0% upside
Current
$2.49
$2.49
Target
$23.78
$23.78
$21.93
$23.78 avg
$37.21
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.63M | 3.74M | 119.79M |
| Net Income | -71,457,824 | -66,219,153 | 199.8K |
| Profit Margin | -1,971.7% | -1,873.1% | 0.2% |
| EBITDA | -67,778,645 | -66,299,127 | 316.5K |
| Free Cash Flow | — | — | 248.3K |
| Rev Growth | -2.9% | -2.9% | -0.9% |
| Debt/Equity | 0.10 | 0.10 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |